Radiopharmaceuticals Market Trends, Size, Top Players 2031
放射性药物市场规模预计将从 2023 年的 90.7 亿美元增至 2031 年的 265.1 亿美元。预计 2023-2031 年期间该市场的复合年增长率将达到 14.4%。使用先进诊断技术的不断发展的放射性药物设施可能会为放射性药物市场带来新的趋势。
放射性药物市场分析
心血管疾病 (CVD) 和癌症等慢性疾病在老龄化人口中越来越常见。随着世界人口老龄化,对医疗干预的需求也在增加,例如使用放射性药物来检测和治疗与年龄相关的疾病。人们对早期疾病检测意识的提高导致放射性药物在诊断成像程序中的使用增加,例如单光子发射计算机断层扫描 (SPECT) 和正电子发射断层扫描 (PET) 扫描。这些技术能够准确识别和表征各种疾病,包括癌症、心脏病和神经系统疾病,从而导致对更多放射性药物的需求不断增长。癌症仍然是全球主要的健康问题,放射性药物在癌症诊断和治疗中都发挥着关键作用。使用放射性示踪剂(例如氟脱氧葡萄糖 (FDG)-PET)的 PET 扫描对于癌症检测和监测非常有效。治疗性放射性药物(例如用于治疗甲状腺癌的放射性碘和用于治疗淋巴瘤的放射性钇)可提供靶向治疗选择。癌症发病率的上升和新型放射性药物癌症疗法的开发是主要的增长动力。此外,制药公司、学术机构和医疗保健提供商之间的合作促进了放射性药物的开发和商业化,为市场提供了未来的增长机会。
放射性药物市场概况
近年来,放射性药物已成为神经内科、心脏病学和肿瘤学等各个领域最有效的技术之一。每种放射性药物都针对身体的特定区域,一旦到达其位置就会释放放射性物质攻击肿瘤细胞。研究人员已经确定了可以对抗甲状腺癌、脑瘤、淋巴瘤和骨癌等肿瘤的放射性药物。传统的癌症化疗方法被更实用的治疗性放射性药物所取代,开辟了新的市场机会。与X射线和其他外部辐射成像系统相比,放射性药物可帮助医生进行诊断,并为患者提供方便、更安全的替代方案。用于诊断目的的放射性药物称为示踪剂。诊断性放射性药物释放的辐射量低于治疗性放射性药物。医学成像技术的发展、慢性病发病率的上升以及对个性化治疗的日益重视,促进了放射性药物市场的大幅增长。核医学在很大程度上依赖于放射性同位素与药物结合产生的放射性药物,从而实现各种疾病的成像和治疗。Radiopharmaceuticals that are used for diagnostic purposes are called tracers. The amount of radiation released from
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
放射性药物市场: Market:
复合年增长率(2023 - 2031)14.4%- 2023 年市场规模
90.7 亿美元 - 2031年市场规模
265.1亿美元
市场动态
- 慢性病患病率上升
- 靶向治疗临床试验数量不断增加
- 放射性药物的保质期短
- 发展中国家的高增长潜力
关键人物;主力;重要一员
- 医疗放射性药物(MRP),
- Rotem 工业有限公司
- ABX Advanced Biochemical Compounds GmbH,
- Invicro LLC,
- 康德乐健康公司,
- 纽卡斯尔大学
- 诺华公司,
- 锔,
- 蓝地球诊断公司
- 通用电气公司
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 肿瘤学
- 心脏病学
- 神经病学
- 肺部
- 泌尿科
- 其他的
- 诊断
- 治疗
- 锝-99m
- F-18
- 镓-68
- TL-201
- I-131
- 铁-59
- 鲁-171
- RB-82 和 N-13
- Cr-51 和 P-32
- SC-46
- Sg-269 和 Hs-269
- 医院和诊所
- 诊断中心
- 学术及研究机构
- 其他的
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
放射性药物市场驱动因素和机遇
靶向治疗临床试验数量不断增加 市场前景看好
已证明阿尔法粒子是内部放射治疗的新来源。它们具有很强的细胞毒性,但与使用贝塔粒子的疗法相比,它们的效果具有高度针对性。尽管靶向阿尔法疗法尚处于开发阶段,但它为对其他治疗方式没有反应的癌症患者带来了生命的希望。发射阿尔法粒子的放射性核素的发展已显示出有希望的结果,可以向癌细胞提供高度局部的辐射剂量,并最大限度地减少对周围健康组织的损害。发射阿尔法粒子的放射性核素具有高线性能量转移和组织内短距离,使其适合某些类型癌症的靶向治疗。人们对阿尔法放射免疫疗法的认识不断提高,癌症治疗程序的疗法可用性激增,推动了对核成像的需求。因此,在癌症治疗中使用阿尔法放射免疫疗法的倾向日益增加,推动了放射性药物市场的增长。
发展中国家的高增长潜力
由于亚洲、南美和非洲等新兴国家各种疾病的发病率上升,许多医疗市场参与者将重点放在这些地区。印度的医疗领域发展迅速,在过去几十年中经历了几次重大变化。发展中国家的研究机构致力于开发先进的诊断系统,包括经济高效、性能卓越的 PET/SPECT 系统。这些发展主要是为了将其覆盖范围扩大到无法获得先进医疗 IT 设施的偏远地区。中国、日本和巴西等新兴国家正在投入巨资开发 PET/SPECT 机器,以降低成本并为医院和其他医疗机构提供更好的使用这些机器的机会。2021 年 3 月,BWXT Medical Ltd. 和 Global Medical Solutions, Ltd. (GMS) 成立合资企业,在亚太地区生产和分销放射性同位素和放射性药物。因此,发展中国家为放射性药物市场参与者扩大其覆盖范围和客户群提供了重要机会。
放射性药物市场报告细分分析
有助于得出放射性药物市场分析的关键部分是应用、示踪剂类型和最终用户。
- 根据应用,市场分为肿瘤科、心脏病科、神经科、肺科、泌尿科等。2023 年,肿瘤科占据了最大的市场份额,预计在 2023-2031 年期间将实现最高的复合年增长率。
- 根据类型,放射性药物市场分为诊断和治疗两大类。2023 年,诊断领域占据了更大的市场份额,预计 2023 年至 2031 年的复合年增长率将更高。
- 根据示踪剂类型,市场细分为 Tc-99m、F-18、Ga-68、TL-201、I-131、Fe-59、Lu-171、RB-82 和 N-13、Cr-51 和 P-32、Sc-46、Sg-269 和 Hs-269 等。2023 年,Tc-99m 部分占据了最大的市场份额,预计在 2023-2031 年期间将实现最高的复合年增长率。
- 根据最终用户,放射性药物市场分为医院和诊所、诊断中心、学术和研究机构等。2023 年,医院和诊所占据了最大的市场份额。预计诊断中心部分在 2023-2031 年期间的复合年增长率最高。
放射性药物市场份额按地区分析
放射性药物市场报告的地理范围主要分为五个地区:北美、亚太、欧洲、中东和非洲、南美和中美。
北美在放射性药物市场占有主导地位。该地区市场的增长归因于慢性病发病率的增加、政府的支持性计划、市场参与者不断增加的战略举措以及创新放射疗法的发展。美国在北美的放射性药物市场中占有最大的份额。由于先进的医疗基础设施、目标疾病发病率和患病率的上升以及该地区主要参与者的产品创新,预计市场将增长。此外,市场参与者还推出了创新产品以提供更好的治疗。例如,2022 年 9 月,MD 安德森癌症中心和 Radiopharm Theranostics 成立了 Radiopharm Ventures, LLC,这是一家开发新型放射性药物治疗癌症产品的合资企业。
放射性药物市场报告范围
报告属性 | 细节 |
---|---|
2023 年的市场规模 | 90.7 亿美元 |
2031 年市场规模 | 265.1亿美元 |
全球复合年增长率(2023 - 2031) | 14.4% |
历史数据 | 2021-2022 |
预测期 | 2024-2031 |
涵盖的领域 | 按应用
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
放射性药物市场新闻和最新发展
放射性药物市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。放射性药物市场的一些发展如下所列:
- Curium 宣布已与 Eczacıbaşı Holding 和 Bozlu Group 达成协议,收购专门从事核医学的 Eczacıbaşı-Monrol Nuclear Product Co. (Monrol)。此次收购预计将整合高度互补的地理覆盖范围、镥-177 (Lu-177) 能力以及 PET 和 SPECT 核医学基础设施,并促进用于诊断和治疗目的的尖端放射性核素和放射性药物管道的开发。(来源:Curium,新闻稿,2024 年 4 月)
- 诺华公司宣布,该公司已获得美国食品药品监督管理局 (FDA) 的批准,可在美国印第安纳州印第安纳波利斯市新建的大型先进放射性配体治疗 (RLT) 制造工厂进行 Pluvicto(INN:lutetium (177Lu) vipivotide tetraxetan/USAN:lutetium Lu 177 vipivotide tetraxetan)的商业化生产。(来源:诺华,新闻稿,2024 年 1 月)
- IBA Radiopharma Solutions、CMI Inc. 和 Life Molecular Imaging (LMI) 宣布,日本卫生部批准政府医疗保险报销淀粉样蛋白正电子发射断层扫描 (PET) 诊断 Neuraceq (florbetaben 18F)。使用 Neuraceq 等药物的淀粉样蛋白 PET 成像可用于诊断阿尔茨海默病和其他形式的认知障碍。它可以检测大脑中的淀粉样斑块,这是阿尔茨海默病的典型标志。(来源:IBA,新闻稿,2023 年 12 月)
- Telix 的 Illuccix 获得了加拿大卫生部的批准,这是一种用于制备镓 (68Ga) 戈泽托肽注射液的试剂盒。该产品可用于中高风险前列腺癌的分期和重新分期以及复发性前列腺癌的肿瘤组织定位。Illuccix 是首个在加拿大获得监管批准的 PSMA PET 成像剂。加拿大卫生部是全球第三个批准 Illuccix 的监管机构,该产品在澳大利亚和美国有售。(来源:Telix,新闻稿,2022 年 10 月)
- GE Healthcare 与 Minerva Imaging 达成战略合作伙伴关系,以加速靶向放射性核素疗法(治疗诊断学)的商业化推出。放射性核素疗法是一种精准医疗,通过血液输送放射性物质以靶向癌细胞并对其进行特异性照射。与传统癌症疗法相比,这有助于减少潜在的副作用。(来源:GE Healthcare,新闻稿,2021 年 12 月)
放射性药物市场报告覆盖范围和交付成果
“放射性药物市场规模和预测(2021-2031)”报告对市场进行了详细分析,涵盖以下领域:
- 放射性药物市场规模及全球、区域和国家层面所有主要细分市场的预测
- 放射性药物市场趋势以及市场动态,如驱动因素、限制因素和关键机遇
- 详细的 PEST/波特五力分析和 SWOT 分析
- 放射性药物市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
- 行业格局和竞争分析,涵盖市场集中度、热图分析、知名参与者以及放射性药物市场的最新发展
- 详细的公司简介
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The radiopharmaceuticals market is expected to register a CAGR of 14.4% during 2023–2031.
The radiopharmaceuticals market is estimated to reach US$ 26.51 billion by 2031.
Evolving radiopharmacy facilities that use advanced diagnostic techniques in PET and radiotherapeutics are likely to bring in new trends in the radiopharmaceutical market.
Curium, ABX advanced biochemical compounds GmbH, and Medi-Radiopharma are among the leading players operating in the radiopharmaceuticals market.
North America dominated the radiopharmaceuticals market in 2023.
The rising prevalence of chronic diseases and the growing number of clinical trials in targeted therapy are the factors driving the radiopharmaceuticals market.
- Medi-Radiopharma (MRP)
- Rotem Industries Ltd.
- ABX Advanced Biochemical Compounds GmbH
- Invicro LLC
- Cardinal Health
- Newcastle University
- Novartis
- Curium
- Blue Earth Diagnostics
- General Electric Company
- IBA Radiopharma Solutions
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.